# Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

> **NCT04925687** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 4 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** Intravitreal autologous CD34+ cells

## Key facts

- **NCT ID:** NCT04925687
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925687, "Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04925687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*